We are live on
!
Find out more
FCMI
Foresite Capital Management III Portfolio holdings
AUM
$37.9M
1-Year Est. Return
6.87%
This Fund
S&P 500
This Quarter
Est. Return
+22.48%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$30.4M
(+13%)
Cap. Flow
-$14.2M
Cap. Flow
% of AUM
-5.45%
Top 10 Holdings %
Top 10 Hldgs %
85.17%
Holding
28
New
8
Increased
4
Reduced
9
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$12M |
| 2 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$6.74M |
| 3 |
DERM
Dermira, Inc.
DERM
|
+$5.69M |
| 4 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$4.12M |
| 5 |
Natera
NTRA
|
+$2.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKAO
Achaogen Inc
AKAO
|
+$28M |
| 2 |
Intellia Therapeutics
NTLA
|
+$7.43M |
| 3 |
Editas Medicine
EDIT
|
+$4.46M |
| 4 |
iRhythm Holdings
IRTC
|
+$3.31M |
| 5 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$2.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
| $72.4M | 27.79% |
1,596,701
-1,751
| -0.1% | -$78.1K |
|
|
ALDR
2
DELISTED
Alder Biopharmaceuticals
ALDR
| $33.9M | 13.01% |
1,629,222
+894
| +0.1% | +$19.8K |
|
|
AKAO
3
DELISTED
Achaogen Inc
AKAO
| $31.4M | 12.06% |
1,245,187
-1,362,797
| -52% | -$28M |
|
|
AIMT
4
DELISTED
Aimmune Therapeutics
AIMT
| $19.8M | 7.61% |
912,001
+8,111
| +0.9% | +$166K |
|
5
Wave Life Sciences
WVE
$1.13B
| $18.6M | 7.14% |
676,128
| – | – |
|
|
EPZM
6
DELISTED
Epizyme, Inc
EPZM
| $11.7M | 4.49% |
681,922
+76,683
| +13% | +$1.02M |
|
|
BLCM
7
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $11.3M | 4.35% |
+91,800
| New | +$12M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $10.4M | 4% |
260,400
-39,600
| -13% | -$1.42M |
|
|
NSTG
9
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.33M | 2.43% |
318,586
-119,547
| -27% | -$2.27M |
|
|
DERM
10
DELISTED
Dermira, Inc.
DERM
| $6.01M | 2.31% |
+176,211
| New | +$5.69M |
|
|
MNTA
11
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $5.75M | 2.21% |
+430,632
| New | +$6.74M |
|
12
Protagonist Therapeutics
PTGX
$8.7B
| $4.44M | 1.7% |
346,281
| – | – |
|
|
LOXO
13
DELISTED
Loxo Oncology, Inc
LOXO
| $4.21M | 1.62% |
+100,000
| New | +$4.12M |
|
14
Aclaris Therapeutics
ACRS
$733M
| $4.17M | 1.6% |
140,000
-15,767
| -10% | -$455K |
|
15
Ascendis Pharma A/S
ASND
$16.3B
| $2.8M | 1.07% |
100,000
-80,000
| -44% | -$2.02M |
|
|
16
iRhythm Holdings
IRTC
$3.81B
| $2.63M | 1.01% |
70,010
-96,200
| -58% | -$3.31M |
|
|
17
Natera
NTRA
$36.7B
| $2.53M | 0.97% |
+285,731
| New | +$2.72M |
|
|
KYNB
18
Kyntra Bio
KYNB
$29M
| $2.17M | 0.83% |
+3,519
| New | +$2.14M |
|
|
19
Intellia Therapeutics
NTLA
$1.46B
| $2.11M | 0.81% |
150,000
-553,563
| -79% | -$7.43M |
|
|
JNCE
20
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.01M | 0.77% |
+91,600
| New | +$1.94M |
|
21
Larimar Therapeutics
LRMR
$390M
| $1.73M | 0.66% |
30,906
-8,211
| -21% | -$408K |
|
|
OREX
22
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $1.31M | 0.5% |
380,530
+126,273
| +50% | +$498K |
|
|
BOLD
23
DELISTED
Audentes Therapeutics, Inc
BOLD
| $1.13M | 0.44% |
66,553
| – | – |
|
|
IMMU
24
DELISTED
Immunomedics Inc
IMMU
| $1.12M | 0.43% |
+172,871
| New | +$876K |
|
|
XLRN
25
DELISTED
Acceleron Pharma
XLRN
| $526K | 0.2% |
19,886
| – | – |
|
Similar funds
PIM
KCGDR
SEM
ALFIA
MCMI
LCM
HLC
KXA
Foresite Capital Management III's Q1 2017 Portfolio in Review
As of Q1 2017, Foresite Capital Management III held 28 positions worth $261M, up 13% from $230M the previous quarter. Its ten largest holdings account for 85% of the portfolio.
Foresite Capital Management III withdrew a net $14.2M in Q1 2017, closing 3 positions and reducing 9 holdings. Its most notable exit was Editas Medicine, an estimated $4.46M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 51% a quarter earlier.
Against the trend, Foresite Capital Management III opened a new position in Bellicum Pharmaceuticals, Inc. worth $11.3M.
- Foresite Capital Management III's largest Q1 2017 buy was Bellicum Pharmaceuticals, Inc.: 91,800 shares worth $11.3M.
- Foresite Capital Management III added most to Epizyme, Inc in Q1 2017, an estimated $1.02M increase.
- Foresite Capital Management III's biggest Q1 2017 reduction was Achaogen Inc, cutting an estimated $28M.
- Foresite Capital Management III fully exited Editas Medicine in Q1 2017, selling an estimated $4.46M.
- Foresite Capital Management III's ten largest holdings make up 85% of its $261M portfolio in Q1 2017.
- Foresite Capital Management III opened 8 new positions and closed 3 in Q1 2017.
- Foresite Capital Management III's portfolio value rose 13% quarter-over-quarter to $261M.
Based on Foresite Capital Management III's 13F filing for Q1 2017, filed 12 May 2017.